Subject(s)

Angiogenesis Inhibitors/adverse effects , Antibodies, Monoclonal/adverse effects , Fibrosarcoma/secondary , Glomerulonephritis, Membranoproliferative/chemically induced , Lung Neoplasms/secondary , Adult , Angiogenesis Inhibitors/therapeutic use , Antibodies, Monoclonal/pharmacology , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Humanized , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bevacizumab , Bowman Capsule/blood supply , Bowman Capsule/physiology , Dacarbazine/administration & dosage , Deoxycytidine/administration & dosage , Deoxycytidine/adverse effects , Deoxycytidine/analogs & derivatives , Disease Progression , Docetaxel , Doxorubicin/administration & dosage , Endothelium, Vascular/drug effects , Endothelium, Vascular/physiopathology , Fibrosarcoma/drug therapy , Fibrosarcoma/surgery , Humans , Ifosfamide/administration & dosage , Lung Neoplasms/drug therapy , Male , Mesna/administration & dosage , Muscle Neoplasms/drug therapy , Muscle Neoplasms/surgery , Podocytes/physiology , Proteinuria/chemically induced , Taxoids/administration & dosage , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Vascular Endothelial Growth Factor A/physiology , Gemcitabine

Subject(s)

Humans , Male , Adult , Angiogenesis Inhibitors/adverse effects , Antibodies, Monoclonal/adverse effects , Glomerulonephritis/chemically induced , Proteinuria/etiology